Crossmark

NLRP3 inhibitor glibenclamide attenuates high-fat diet and streptozotocin-induced non-alcoholic fatty liver disease in rat: studies on oxidative stress, inflammation, DNA damage and insulin signalling pathway

Crossref DOI link: https://doi.org/10.1007/s00210-019-01773-5

Published Online: 2019-12-13

Published Print: 2020-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Dwivedi, Durgesh Kumar

Jena, G. B. https://orcid.org/0000-0001-9437-7252
Funding

Funding for this research was provided by:

National Institute of Pharmaceutical Education and Research, S A S Nagar, Punjab, India
License Information

Text and Data Mining valid from 2019-12-13

Version of Record valid from 2019-12-13
More Information

Article History

Received: 16 July 2019

Accepted: 12 November 2019

First Online: 13 December 2019

Compliance with ethical standards

: The animal protocol was approved by the Institutional Animal Ethics Committee (IAEC) against approval number IAEC/16/54.

: The authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below